AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31995012 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine + β-blocker (n=1,089)
Number of subjects: 3293
Study 31995012 — intervention group
Group type: COMPARATOR
Intervention: Benidipine + thiazide (n=1,094)
Number of subjects: 3293
Study 31995012 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine + ARB (n=1,110)
Number of subjects: 3293
Study 31995012 — intervention group
Group type: EXPERIMENTAL
Intervention: All three regimens (benidipine + ARB, β-blocker, thiazide)
Number of subjects: 3293
Study 31995587 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic asthma
Number of subjects: 56
Study 31995587 — intervention group
Group type: EXPERIMENTAL
Intervention: Der p 1-specific sputum IgE levels in allergic asthmatics
Number of subjects: 56
Study 31995587 — intervention group
Group type: COMPARATOR
Intervention: Total sputum IgE
Number of subjects: 56
Study 31995587 — intervention group
Group type: COMPARATOR
Intervention: Total IgE levels measured in serum and induced sputum
Number of subjects: 56
Study 31995587 — intervention group
Group type: COMPARATOR
Intervention: Der p 1-specific IgE levels
Number of subjects: 56
Study 31995602 — intervention group
Group type: EXPERIMENTAL
Intervention: CalPen web-based tool for estimating penetrance
Number of subjects: 134
Study 31995668 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine gastrin-releasing peptide (GRP) levels more than 80 in the first postnatal week
Number of subjects: 257
Study 31995668 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine gastrin-releasing peptide (GRP) levels
Number of subjects: 257
Study 31996201 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-oral endoscopic thyroid surgery
Number of subjects: 70
Study 31996201 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 70
Study 31996246 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hope measure developed and validated among PLH
Number of subjects: 722
Study 31996250 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated noncommunicable disease care management intervention leveraging WHO-PEN and HEARTS guidelines.
Number of subjects: 80000
Study 31996898 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with gynecomastia
Number of subjects: 124
Study 31996919 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 84
Study 31996919 — intervention group
Group type: COMPARATOR
Intervention: Normal weight
Number of subjects: 84
Study 31997646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 0
Study 31997646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31997819 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells (hUC-MSCs)
Number of subjects: 66
Study 31997819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31998111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Number of subjects: 0
Study 31998111 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study 31998285 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal antibiotic treatment
Number of subjects: 0
Study 31998285 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving antibiotics)
Number of subjects: 0
Study 31998295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterial Growth Inhibition Assays (MGIAs)
Number of subjects: 0
Study 31998643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ipilimumab (IPI) 10 mg/kg IV every 3 weeks for four doses starting at week 1 and high-dose interleukin-2 (IL-2) 600,000 IU/kg IV bolus every 8 h for up to 14 doses concurrently with IPI at weeks 4 and 7.
Number of subjects: 9
Study 31998643 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance IPI (10 mg/kg IV) monotherapy administered every 12 weeks for up to 1 year after the first 12 weeks of combination therapy.
Number of subjects: 9
Study 31998643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with high-dose IPI and high-dose IL-2.
Number of subjects: 9
Study 31998651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based community (WalkON®) for 12 weeks
Number of subjects: 0
Study 31998651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile community-later arm
Number of subjects: 0
Study 31998651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile community-first arm
Number of subjects: 0
Study 31998847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 0
Study 31998847 — intervention group
Group type: COMPARATOR
Intervention: Aspirin withdrawal
Number of subjects: 0
Study 31998858 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn Soy Blend Plus with oil (CSB+ w/oil)
Number of subjects: 0
Study 31998858 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn Soy Whey Blend with oil (CSWB w/oil)
Number of subjects: 0
Study 31998858 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+)
Number of subjects: 0
Study 31998858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 0
Study 31998859 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisectoral household agricultural and finance intervention including a human-powered water pump, microfinance loan for farm commodities, and training in sustainable farming practices and financial management.
Number of subjects: 200
Study 31998859 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention details provided).
Number of subjects: 200
Study 31998871 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Mode adhesives
Number of subjects: 0
Study 31998871 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31999044 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfapump
Number of subjects: 30
Study 31999167 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading errors scored as 'contralesional' (error in the left half of the word)
Number of subjects: 110
Study 31999167 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelwise lesion-symptom analysis (VLSM)
Number of subjects: 110
Study 31999499 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn injury patients
Number of subjects: 47
Study 31999499 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 47
Study 31999736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pox-protein clade AE/B alum-adjuvanted regimen (PAE/B/alum)
Number of subjects: 0
Study 31999736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pox-protein clade C/C MF59-adjuvanted regimen (PC/MF59)
Number of subjects: 0
Study 31999736 — intervention group
Group type: EXPERIMENTAL
Intervention: HVTN 702 trial
Number of subjects: 0